Harrow Health, Inc. (HROW) Investor Relations Documents

Harrow Health, Inc. (HROW) investor relations documents from the company's IR site: 7 presentations, 22 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

Presentation: Harrow's August 2026 Corporate Presentation details its position as a diversified ophthalmic pharma company, highlighting strong revenue growth and a robust product pipeline with

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10PresentationPresentation
2026-08-10Press releaseHarrow Announces Second Quarter 2026 Financial Results
2026-08-06Press releaseHarrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
2026-07-27Press releaseHarrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
2026-07-20Press releaseSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® /
2026-07-20Press releaseHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
2026-07-01Press releaseHarrow Announces Commercial Launch of BYOOVIZ® in the United States
2026-06-10Press releaseHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Signifi
2026-06-01PresentationWilliam Blair 46th Annual Growth Stock Conference
2026-05-27Press releaseHarrow to Present at William Blair’s 46th Annual Growth Stock Conference
2026-05-11PresentationPresentation
2026-05-11Press releaseHarrow Announces First Quarter 2026 Financial Results
2026-04-27Press releaseHarrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
2026-04-16Press releaseHarrow Announces the Issuance of J-Code for IOPIDINE® 1%
2026-03-24Press releaseHarrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
2026-03-08PresentationLeerink Conference Presentation
2026-03-04Press releaseHarrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
2026-03-02PresentationPresentation
2026-03-02Press releaseNews
2026-02-18Press releaseHarrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
2026-02-02Press releaseHarrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
2025-11-10PresentationPresentation
Press releaseHarrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
2025-10-02PresentationPresentation
Press releaseEarnings Release
Press releaseHarrow Announces First-Quarter 2025 Financial Results
Press releaseHarrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
2023-07-18Press releaseHarrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
2020-09-11Press releaseHarrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020

HROW overview · HROW earnings · HROW financials · HROW KPIs · HROW documents · HROW ownership · HROW peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.